Fibroblast Activation Protein-Targeted Radioligand Therapy with (177)Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study

PURPOSE: Fibroblast activation protein (FAP) is a promising target for tumor treatment. In this study, we aimed to investigate the safety and efficacy of the albumin binder-conjugated FAP-targeted radiopharmaceutical, (177)Lu-EB-FAPI ((177)Lu-LNC1004), in patients with metastatic radioiodine-refract...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Hao, Huang, Jingxiong, Zhao, Tianzhi, Wang, Hongjian, Chen, Yuhang, Xu, Weizhi, Pang, Yizhen, Guo, Wei, Sun, Long, Wu, Hua, Xu, Pengfei, Su, Bishan, Zhang, Jingjing, Chen, Xiaoyuan, Chen, Haojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690094/
https://www.ncbi.nlm.nih.gov/pubmed/37801296
http://dx.doi.org/10.1158/1078-0432.CCR-23-1983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690094/
https://www.ncbi.nlm.nih.gov/pubmed/37801296
http://dx.doi.org/10.1158/1078-0432.CCR-23-1983

Ejemplares similares